4:35 PM
 | 
Jul 09, 2018
 |  BC Extra  |  Financial News

Abingworth closes BioVentures VII fund at $315M

Abingworth Management Ltd. closed its BioVentures VII fund at $315 million, exceeding the fund's $300 million target. Funds will be invested in the U.S. and Europe.

Abingworth's therapeutic interests for BioVentures VII include next-generation cell therapies, antivirals and...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >